BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31677021)

  • 1. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
    Shibutani T; Nagao S; Suzuki K; Kaneda M; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Sudo T; Yamaguchi S
    Int J Clin Oncol; 2020 Mar; 25(3):502-507. PubMed ID: 31677021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
    Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
    Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
    Ebata T; Yunokawa M; Bun S; Shimomura A; Shimoi T; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1283-1288. PubMed ID: 27832327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
    Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
    Yoshihama T; Nomura H; Iwasa N; Kataoka F; Hashimoto S; Nanki Y; Hirano T; Makabe T; Sakai K; Yamagami W; Hirasawa A; Aoki D
    Jpn J Clin Oncol; 2017 Nov; 47(11):1019-1023. PubMed ID: 28973541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dense approaches to ovarian cancer treatment.
    Katsumata N
    Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    Park SJ; Shim SH; Ji YI; Kwon SH; Lee EJ; Lee M; Chang SJ; Park S; Kim SY; Lee SJ; Kim JW; Roh JW; Lee SH; Song T; Kim HS
    BMC Cancer; 2020 May; 20(1):385. PubMed ID: 32375688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
    Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.
    Iwasa-Inoue N; Nomura H; Kataoka F; Chiyoda T; Yoshihama T; Nanki Y; Sakai K; Kobayashi Y; Yamagami W; Morisada T; Hirasawa A; Aoki D
    Int J Clin Oncol; 2022 Feb; 27(2):441-447. PubMed ID: 34648082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
    Onda T; Satoh T; Ogawa G; Saito T; Kasamatsu T; Nakanishi T; Mizutani T; Takehara K; Okamoto A; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Kanao H; Watanabe Y; Yamamoto K; Yaegashi N; Kamura T; Yoshikawa H;
    Eur J Cancer; 2020 May; 130():114-125. PubMed ID: 32179446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
    Takaya H; Nakai H; Murakami K; Tobiume T; Suzuki A; Mandai M; Matsumura N
    Int J Clin Oncol; 2018 Aug; 23(4):698-706. PubMed ID: 29572761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
    Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
    Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
    J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
    Tiersten AD; Liu PY; Smith HO; Wilczynski SP; Robinson WR; Markman M; Alberts DS
    Gynecol Oncol; 2009 Mar; 112(3):444-9. PubMed ID: 19138791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study.
    Vrdoljak J; Boban T; Petrić Miše B; Boraska Jelavić T; Bajić Ž; Tomić S; Vrdoljak E
    Jpn J Clin Oncol; 2019 Apr; 49(4):347-353. PubMed ID: 30796833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
    Glaze S; Teitelbaum L; Chu P; Ghatage P; Nation J; Nelson G
    J Obstet Gynaecol Can; 2013 Jan; 35(1):61-7. PubMed ID: 23343799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.